Comparative Pharmacology
Head-to-head clinical analysis: ALUNBRIG versus BOSUTINIB MONOHYDRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUNBRIG versus BOSUTINIB MONOHYDRATE.
ALUNBRIG vs BOSUTINIB MONOHYDRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alunbrig (brigatinib) is a tyrosine kinase inhibitor that targets ALK and ROS1. It inhibits autophosphorylation of ALK and ALK-mediated activation of downstream signaling proteins STAT3, AKT, ERK1/2, and PLCγ in ALK-dependent tumor cells.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor. It inhibits the BCR-ABL kinase, which is constitutively active in chronic myeloid leukemia (CML), and also inhibits Src family kinases. It has minimal inhibitory activity against c-KIT and PDGFR.
90 mg orally once daily for first 7 days, then increase to 180 mg orally once daily
400 mg orally once daily with food.
None Documented
None Documented
Terminal half-life approximately 25 hours. Supports once-daily dosing; steady state achieved in ~5 days.
22.5 hours; supports once-daily dosing, with steady-state achieved by day 8.
Primarily hepatic metabolism (CYP3A4); 65% fecal (unchanged and metabolites), 25% renal (1% unchanged). Biliary excretion contributes to fecal elimination.
Primarily fecal (91%, as unchanged drug and metabolites) with renal excretion accounting for <3%.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor